Enlivex Therapeutics Ltd
ENLV
View Detailed Chart
0.920USD
-0.130-12.38%
Market hours （ET）Quotes delayed by 15 min
327.30KMarket Cap
0.03P/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-12.38%
5 Days
-9.80%
1 Month
-20.00%
6 Months
-8.91%
Year to Date
+30.83%
1 Year
-9.80%
View Detailed Chart
TradingKey Stock Score of Enlivex Therapeutics Ltd
Currency: USD Updated: 2026-03-27Key Insights
Enlivex Therapeutics Ltd's fundamentals are relatively weak, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 190 out of 391 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 13.00.In the medium term, the stock price is expected to trend up.The company has shown weak stock market performance over the past month, in line with its weak fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Enlivex Therapeutics Ltd's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Enlivex Therapeutics Ltd Highlights
StrengthsRisks
Enlivex Therapeutics Ltd is an Israel-based clinical stage macrophage reprogramming immunotherapy company developing Allocetra, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. AllocetraTM is a therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, COVID-19 and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, AllocetraTM has the potential to provide immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as unmet medical needs, as a stand-alone therapy or in combination with therapeutic agents.
Turnaround to Profit
The company's performance has turned profitable, with the latest annual net income of USD .
Overvalued
The company’s latest PE is 0.04, at a high 3-year percentile range.
Held by James Simons
Star Investor James Simons holds 313.63K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 5.81.
Analyst Rating
Based on
2
analysts
Buy
Current Rating
13.000
Target Price
+1092.66%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Enlivex Therapeutics Ltd News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Enlivex Therapeutics Ltd Info
Enlivex Therapeutics Ltd is an Israel-based clinical stage macrophage reprogramming immunotherapy company developing Allocetra, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. AllocetraTM is a therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, COVID-19 and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, AllocetraTM has the potential to provide immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as unmet medical needs, as a stand-alone therapy or in combination with therapeutic agents.
Ticker SymbolENLV
CompanyEnlivex Therapeutics Ltd
CEOHershkovitz (Oren)
Websitehttps://www.enlivex.com/
Related Instruments
-0.98%
+1.69%
+0.76%
+3.08%
-0.71%
+0.94%
+0.69%
+0.34%
+0.17%
+0.27%
-2.90%
+0.46%
+0.72%
+0.91%
-2.71%
0.00%
-0.21%
-0.74%
-0.53%
+1.08%Popular Symbols
246.370
-2.430 (-0.98%)
165.490
-2.030 (-1.21%)
66581.710
-2.340 (-0.00%)
252.335
-21.015 (-7.69%)
2027.140
+27.140 (+1.36%)
355.555
-6.275 (-1.73%)
4499.580
+7.060 (+0.16%)
102.482
+1.873 (+1.86%)
1.146
-0.005 (-0.40%)
159.626
-0.626 (-0.39%)
